利拉鲁肽治疗患者因低镁血症继发低钙血症。
Hypocalcemia secondary to hypomagnesemia in a patient on liraglutide.
作者信息
Habnouny J E L, Jandou I, Latrech H, Bourgon C
机构信息
Department of Endocrinology, Diabetology, CHU Mohammed VI, Laboratory of Epidemiology and clinical research and public Health, Faculty of Medicine and Pharmacy, Mohamed Premier University, Oujda, Morocco.
Department of Medicine 6, Lons le Saunier Hospital Center, Jura-Sud, France.
出版信息
Ann Med Surg (Lond). 2020 Oct 29;60:327-329. doi: 10.1016/j.amsu.2020.10.052. eCollection 2020 Dec.
A 73-year-old man with type 2 diabetes on Liraglutide with a history of coronary artery disease. Admitted to emergency for abdominal pain, severe diarrhea and episodes of tetany attacks. Laboratory workup reveals hypomagnesemia, hypocalcemia and normal parathormone (PTH). After intravenous administration of magnesium and calcium, the blood ionogram quickly normalized. In addition, plasma levels of intact parathyroid hormone increased immediately after magnesium administration. Strongly suggests that hypocalcemia resulted from a disruption of adequate parathyroid hormone secretion caused by hypomagnesemia which in turn was caused by severe diarrhea under treatment with Liraglutide.
一名73岁的2型糖尿病男性患者，正在使用利拉鲁肽治疗，有冠状动脉疾病史。因腹痛、严重腹泻和手足搐搦发作而急诊入院。实验室检查发现低镁血症、低钙血症，甲状旁腺激素（PTH）水平正常。静脉输注镁和钙后，血液离子图迅速恢复正常。此外，输注镁后血浆中完整甲状旁腺激素水平立即升高。强烈提示低钙血症是由低镁血症导致的甲状旁腺激素分泌不足引起的，而低镁血症又是由正在接受利拉鲁肽治疗的严重腹泻所致。
Zotero 插件